Update on pharmacogenetics in cancer chemotherapy

European Journal of Cancer

Volumn 38, Issue 5, 2002, Pages 639-644

  Innocenti, F ^a   Ratain, M J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cancer; Chemotherapy; Pharmacogenetics; Response; Toxicity

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); 7 ETHYL 10 HYDROXYCAMPTOTHECIN; AMONAFIDE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLAVOPIRIDOL; FLUOROURACIL; GLUTATHIONE TRANSFERASE; IRINOTECAN; MERCAPTOPURINE; METHOTREXATE; RALTITREXED; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; BREAST CARCINOMA; CANCER CHEMOTHERAPY; DISEASE ASSOCIATION; DRUG METABOLISM; DRUG SENSITIVITY; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC STRAIN; HUMAN; ONCOLOGY; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; TOXICITY; TREATMENT OUTCOME;

EID: 0036202663     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00434-8     Document Type: Article

References (59)

1. Pharmacogenetics: A tool for individualizing antineoplastic therapy
2. Pharmacogenetics of anticancer agents: Lessons from amonafide and irinotecan
3. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia
4. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus
5. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine
6. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia
7. Segregation analysis of human red blood cell thiopurine methyltransferase activity
8. Promoter and intronic sequences of the human thiopurine S-methyltransferase (TPMT) gene isolated from a human PAC1 genomic library
9. Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population
10. Characterization of a variable number tandem repeat region in the thiopurine S-methyltransferase gene promoter
11. Influence of the variable number of tandem repeats located in the promoter region of the thiopurine methyltransferase gene on enzymatic activity
12. Thiopurine methyltransferase polymorphic tandem repeat: Genotype-phenotype correlation analysis
13. Genomic structure and multiple single-nucleotide polymorphisms (SNPs) of the thiopurine S-methyltransferase (TPMT) gene
14. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy
15. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity
16. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: Identification of new mutations in the DPD gene
17. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: Frequency of the common IVS14+1G>A mutation causing DPD deficiency
18. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU) - Related toxicity compared with controls
19. Known variant DPYD alleles do not explain DPD deficiency in cancer patients
20. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls
21. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome
22. Genetic variation in bilirubin UDP-glycuronyltransferase gene promoter and Gilbert's syndrome
23. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism?
24. UGT1A1 28 polymorphism as a determinant of irinotecan disposition and toxicity
25. The genetic basis of Gilbert's syndrome
26. Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: A common missense mutation among Japanese, Koreans and Chinese
27. Neonatal hyperbilirubinemia and a common mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese
28. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis
29. MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF)
30. A common methylenetetrahydrofolate reductase gene mutation and longevity
31. Biological and clinical implications of the MTHFR C677T polymorphism
32. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase
33. A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells
34. Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer
35. Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells
36. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and-resistant human cancer cell lines
37. Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil
38. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors
39. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin
40. Role in translation of a triple tandemly repeated sequence in the 5′-untranslated region of human thymidylate synthase mRNA
41. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase
42. Novel thymidylate synthase enhancer region alleles in African populations
43. Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers
44. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer
45. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer
46. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy
47. Allelotype of colorectal carcinomas
48. Thymidylate synthase promoter polymorphism
49. Searching expressed sequence tag databases: Discovery and confirmation of a common polymorphism in the thymidylate synthase gene
50. Structural analysis of cDNA encoding thymidylate synthase in hepatic metastases of human colorectal tumors
51. Glutathione S-transferase polymorphisms and their biological consequences
52. Glutathione-S-transferase family of enzymes
53. Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer
54. Association of glutathione S-transferase GSTM1 and GSTT1 null genotypes with clinical outcome in epithelial ovarian cancer
55. Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: A case-control study
56. Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia
57. Metabolism of epirubicin to glucuronides: Relationship to the pharmacodynamics of the drug
58. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea
59. Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer